OptiBiotix Health PLC Appointment of Commercial Director (3790T)
05 January 2017 - 7:00AM
UK Regulatory
TIDMOPTI
RNS Number : 3790T
OptiBiotix Health PLC
05 January 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of New Commercial Director
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces the departure of Jim Laird by mutual
agreement and the appointment of Per Rehné as Commercial Director.
Per will join the OptiBiotix Board subject to completion of the
normal regulatory due diligence.
Per has many years experience of the food industry, having
worked for some of the world's leading food companies including
Danisco (acquired by Dupont in 2011 for US$6.3bn), and specialised
food ingredient suppliers including roles as Managing Director of
both Frutarom Nordic A/S (A subsidiary of Frutarom Industries Ltd)
and Innotaste Nordic A/S. More recently, Per has worked as European
Director of Health and Nutrition at Cornelius Group plc which under
his leadership became the company's fastest growing business unit,
quadrupling sales from a low base to double digit million pound
revenues in less than three years.
Per has extensive experience in building business-to-business
sales through commercial partnerships and working with
manufacturers and distributors to rapidly grow sales revenues in
international markets. A proven Commercial Director, Per comes with
a wide network of contacts in the food industry and a track record
of closing out commercial deals.
Per is a qualified food technologist and is multilingual in
English, Danish, German, Swedish and Norwegian. His experience of
food, health, and nutrition markets will help drive
commercialisation of OptiBiotix's growing pipeline of products and
create multiple revenue streams across all technology
platforms.
Stephen O'Hara, CEO of OptiBiotix, commented: "Per's experience
and track record of growing business-to-business sales of
ingredients and nutritional products brings operational commercial
and industry expertise to OptiBiotix. His network of contacts
provides access to new international markets to help drive revenue
growth from OptiBiotix's growing pipeline of products now entering
their commercialisation phase. These include OptiBiotix's patented
SlimBiome technology for hunger free weight loss and its LP-LDL
probiotic strain for cholesterol and hypertension reduction. This
is consistent with the overall aim of developing multiple revenue
streams from both consumer and pharmaceutical products across all
OptiBiotix's technology platforms. On behalf of the Board, I would
like to thank Jim for his hard work and dedication to the Company
and we wish him well in his future projects."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213
0883
Liam Murray
finnCap Broker Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or
optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUSVBRBKAARAR
(END) Dow Jones Newswires
January 05, 2017 02:00 ET (07:00 GMT)